Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 2/20 | 0.40 |
| ▸ | ADH1C | P00326 | 2/20 | 0.40 |
| ▸ | ADH1A | P07327 | 2/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998765 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL998767 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL998954 | 1.00 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL1000295 | 0.97 | ALDH1A1 (0.61) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL1002568 | 0.97 | ALDH1A1 (0.61) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL17636059 | 0.93 | ALDH1A1 (0.57) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL18533009 | 0.92 | ALDH1A1 (0.55) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL999820 | 0.92 | ALDH1A1 (0.53) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL999821 | 0.92 | ALDH1A1 (0.53) | ALDH1A1HSD17B10EPHX1CA12CA7 | |
| SCHEMBL22856385 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HSD17B10EPHX1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322792-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS, LLC | 2023-10-12 | — | — | US | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| EP-1723128-B1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-11-07 | — | — | EP | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| CN-102516240-A | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-06-27 | — | — | CN | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| CN-1910166-B | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-01-04 | — | — | CN | disclosed |
| US-7999114-B2 | Dicycloalkylcarbamoyl ureas as glucokinase activators | NOVO NORDISK A/S (DK) | 2011-08-16 | — | — | US | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | NOVO NORDISK A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| EP-1904438-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2007-03-08 | — | — | US | disclosed |
| CN-1910166-A | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006761-A1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322792-A1 | CDK9 INHIBITORS | CDK9, CDK19, CDK3 | ALDH1A1 4388/4885HSD17B10 3744/4885EPHX1 3487/4885 |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | ALDH1A1 3782/4885HSD17B10 1699/4885EPHX1 4485/4885 |
| US-20080319028-A1 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators | GCK, HK1, GCKR | ALDH1A1 2374/4885HSD17B10 1570/4885EPHX1 4231/4885 |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | ALDH1A1 1548/4885HSD17B10 675/4885EPHX1 3937/4885 |
| US-20070054897-A1 | 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | GCK, GCKR, HK1 | ALDH1A1 520/4885HSD17B10 1182/4885EPHX1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.